Logo

ARTV

Artiva Biotherapeutics, Inc.

ARTV

Artiva Biotherapeutics, Inc. • NASDAQ
$3.76 ▲ 5.03% (+0.18)
Market Cap $92.29 M
52w High $13.14
52w Low $1.47
Dividend Yield 0%
P/E -3.03
Volume 52.47K
Outstanding Shares 24.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $22.235M ▼ $-21.528M ▼ 0% $-0.88 ▼ $-20.866M ▲
Q2-2025 $0 $22.81M ▲ $-21.254M ▼ 0% $-0.87 ▼ $-22.169M ▼
Q1-2025 $0 $22.171M ▲ $-20.311M ▼ 0% $-0.83 ▼ $-21.543M ▼
Q4-2024 $0 $18.267M ▼ $-9.215M ▲ 0% $-0.82 ▲ $-17.653M ▲
Q3-2024 $0 $18.335M $-17.472M 0% $-0.92 $-17.708M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $122.968M ▼ $148.862M ▼ $19.638M ▼ $129.224M ▼
Q2-2025 $142.365M ▼ $169.391M ▼ $20.35M ▼ $149.041M ▼
Q1-2025 $165.963M ▼ $191.263M ▼ $22.48M ▼ $168.783M ▼
Q4-2024 $185.428M ▲ $209.581M ▼ $22.94M ▼ $186.641M ▼
Q3-2024 $146.631M $225.596M $24.6M $200.996M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.528M ▼ $-19.201M ▲ $16.278M ▼ $-37K ▲ $-2.96M ▼ $-19.801M ▲
Q2-2025 $-21.254M ▼ $-22.983M ▼ $21.122M ▲ $-72K ▼ $-1.933M ▲ $-24.038M ▼
Q1-2025 $-20.311M ▼ $-19.841M ▼ $9.971M ▲ $239K ▲ $-9.631M ▲ $-20.352M ▼
Q4-2024 $-16.095M ▲ $-14.65M ▼ $-966K ▲ $-30K ▼ $-15.646M ▼ $-14.714M ▼
Q3-2024 $-17.472M $-11.611M $-130.628M $163.872M $21.633M $-11.707M

Five-Year Company Overview

Income Statement

Income Statement Artiva is still a research-stage biotech company, so it has almost no product revenue yet. The income statement is driven mainly by research and development and other operating costs, which means the company has been reporting steady losses each year. Losses have grown as the company has invested more in its pipeline, which is typical for a young biotech but also means future progress must justify this spending. Profitability is not in sight yet and will depend heavily on future clinical and partnering milestones rather than any current commercial business.

Balance Sheet

Balance Sheet The balance sheet shows a small but improving asset base, with cash as the key resource. Equity has moved from negative to positive recently, which likely reflects new capital raised around the public listing and a cleanup of the capital structure. Debt levels appear modest, so the company does not seem heavily burdened by borrowings. Overall, the balance sheet looks like that of an early-stage biotech: cash-rich relative to its size, but fully dependent on that cash to fund ongoing trials.

Cash Flow

Cash Flow Artiva consistently uses cash in its operations, reflecting its active R&D programs and lack of meaningful revenue. There is also some spending on equipment and related needs, but the main drain on cash is running clinical studies and building the platform. The company relies on external financing—equity raises and potentially partnerships—to replenish its cash. Future funding needs will remain a central issue until there is either a significant partnership inflow or a commercial product.

Competitive Edge

Competitive Edge Artiva is competing in a crowded but promising area: cell therapies for cancer and autoimmune disease, with a focus on natural killer (NK) cells. Its main edge is a manufacturing-first strategy that aims to produce large numbers of “off‑the‑shelf” NK cell doses from cord blood, potentially lowering cost and improving access compared with customized cell therapies. The partnership with GC Cell gives it deep manufacturing know‑how and a head start in scaling production, which could be hard for smaller peers to match. However, competition from other NK and CAR‑T developers is intense, and larger companies with more capital could move quickly if this area proves successful, so maintaining differentiation and speed will be critical.

Innovation and R&D

Innovation and R&D Innovation is the core of Artiva’s story. The lead program, AlloNK (AB‑101), uses non‑genetically modified NK cells to boost the effect of existing antibodies, with early signals in blood cancers and a new push into autoimmune diseases like lupus nephritis. Behind that, the company is building CAR‑NK programs (such as AB‑201 and AB‑202) to target specific tumor markers, seeking the precision of CAR‑T with what could be a better safety and convenience profile. The overall R&D strategy is to marry scalable, off‑the‑shelf manufacturing with a pipeline that can span both oncology and autoimmune conditions, but all of this remains to be proven in larger, later‑stage trials.

Summary

Artiva is a newly public, clinical‑stage biotech with a clear focus: scalable, off‑the‑shelf NK cell therapies for cancer and autoimmune disease. Financially, it fits the classic early‑stage biotech pattern—minimal revenue, ongoing losses, negative operating cash flow, and a balance sheet that depends on fresh capital to support trials. Strategically, its manufacturing platform, GC Cell partnership, and focus on NK cells give it a distinct angle in a high‑potential but highly competitive field. The company’s future will largely be determined by upcoming clinical data, its ability to secure additional funding or partnerships, and how well it can turn a promising scientific and manufacturing concept into durable clinical and commercial outcomes.

NEWS

November 12, 2025 · 7:20 AM UTC

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Read more

November 12, 2025 · 7:00 AM UTC

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more

November 3, 2025 · 4:05 PM UTC

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Read more

October 30, 2025 · 4:17 PM UTC

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Read more

October 16, 2025 · 4:05 PM UTC

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Read more